Johnson & Johnson said an arbitration panel rejected several claims and allegations by Basilea Pharmaceutica AG over the development of the antibiotic ceftobiprole. The panel found J&J breached its licensing agreement with Basilea, J&J said in an e-mailed statement. J&J said it couldn’t disclose further details.
To contact the reporter on this story: Elizabeth Lopatto in New York at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com